Our pipeline As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential specialty medicines and vaccines that help us to get ahead of disease together Our pipeline Assets 71 Medicines and vaccines in the pipeline in 2024 Research & development £6.4bn R&D ...
Our pipeline As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential specialty medicines and vaccines that help us to get ahead of disease together Our pipeline Assets 71 Medicines and vaccines in the pipeline in 2024 Research & development £6.4bn R&D ...
Our pipeline As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential specialty medicines and vaccines that help us to get ahead of disease together Our pipeline Assets 71 Medicines and vaccines in the pipeline in 2024 Research & development £6.4bn R&D ...
From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first. Expand all Disclosure of payments ...
Pipeline 71 vaccines and medicines in development Innovation Trust 1st in the Access to Medicine Index for 8th consecutive time Responsibility Performance £30.3bn group turnover in 2023, AER 3% CER 5% Investors Our leadership team Find out more about our board and global leadership team who ...
More than two-thirds of the vaccines in its clinical pipeline come from in-licensing or other alliances with exter- nal partners. GSK welcomes partnerships on projects that span discovery to late-phase development, to accelerate vaccine development, and strengthen supply (Fig. 1). Ultimately, ...
We continued to strengthen our late-stage pipeline with organic R&D delivery and targeted business development, supporting future growth. £6.4bn R&D investment in 2024 14 R&D focused on 14 medicines and vaccines launching 2025-31, each with potential sales of more than £2bn 71 assets ...
Tony Wood, Chief Scientific Officer, GSK, said: “Affinivax’s exciting pneumococcal vaccine candidates, the potentially disruptive MAPs technology and their fantastic scientific talent, further strengthen our pipeline of novel vaccines and presence in the Boston area”. In the adult phase I/II clinic...
GSK works to protect people from infectious disease by active life-cycle management of existing vaccines, and by fast-tracking the delivery of a pipeline of new vaccines. After more than a year defined by COVID-19, the need for innovative technologies to accelerate vaccine discovery, development...
Welcome to GSK Medical for Canadian health care professionals (HCPs). Explore scientific and disease information, pipeline updates, HCP-directed learning, conferences, and other resources across therapy areas.Oncology EXPLORE Vaccines EXPLORE Respiratory EXPLORE Hepatology EXPLORE ...